NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment
Alexandra Frazao(Hôpital Saint-Louis), Anne Caignard(Inserm), Antoine Toubert(Inserm), Nicolas Dulphy(Inserm), Marie‐Françoise Avril(Délégation Paris 7), Louise Rethacker(Inserm), Meriem Messaoudene(Centre Hospitalier de l’Université de Montréal)
Cited by 95
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
|Nature Immunology|2017|639
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
|Nature Medicine|2022|637
Classification of current anticancer immunotherapies
|Oncotarget|2014|469
Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
|Journal of Clinical Oncology|2011|463